Modulators of resistant androgen receptor

Patent metadata

Field	Value
Publication number	US-11739069-B2
Application number	US-201916658245-A
Country	US
Kind code	B2
Filing date	Oct 21, 2019
Priority date	Oct 26, 2012
Publication date	Aug 29, 2023
Grant date	Aug 29, 2023

Abstract

The present invention provides compounds useful as modulators, agonists or antagonists of androgen receptor (AR), compositions thereof, and methods of making and using the same.

First claim

We claim:

1. A method of treating an androgen receptor (AR)-mediated disease or disorder in a subject comprising administering a first AR modulator, wherein the first AR modulator is of formula I

or a pharmaceutically acceptable salt thereof, wherein:
X is CH or N; and
Z is Ring B;
Ring B is an optionally substituted 6-14 membered saturated or partially unsaturated carbocyclic monocyclic or bicyclic ring, wherein said ring is spiro-fused at point Z; in combination with a secondary agent; and

the (AR)-mediated disease or disorder is a prostate cancer.

2. The method of claim 1 , wherein Ring B is an optionally substituted cyclohexyl ring.

3. The method of claim 2 , wherein X is CH.

4. The method of claim 1 , wherein the first AR modulator is selected from:

5. The method of claim 1 , wherein the secondary agent is a second AR modulator, an anti-cancer agent, a cytotoxin, a chemotherapeutic agent, a radiotherapeutic agent, a palliative agent, a pain reliever, an anti-emetic agent, an anti-nausea agent, or an anti-inflammatory agent.

6. The method of claim 5 , wherein the secondary agent is a second AR modulator.

7. The method of claim 5 , wherein the second AR modulator is selected from the group consisting of non-steroidal antiandrogens, aminoglutethimide, enzalutamide, bicalutamide, nilutamide, flutamide, steroidal antiandrogens, finasteride, dutasteride, bexlosteride, izonsteride, turosteride, epristeride, inhibitors of 5-alpha-reductase, 3,3′-diindolylmethane (DIM), and N-butylbenzene-sulfonamide (NBBS).

8. The method of claim 1 , wherein the secondary agent is an anti-cancer agent.

9. The method of claim 1 , wherein the prostate cancer is castration-resistant prostate cancer.

Assignees

• Memorial Sloan Kettering Cancer Center

Inventors

• Balbas Minna D
• Evans Michael J
• Sawyers Charles L
• Shen Yang
• Hosfield David
• Greene Geoffrey L

Classifications

• C07D401/04 Primary

  directly linked by a ring-member-to-ring-member bond · CPC title

• C07D233/86

  Oxygen and sulfur atoms, e.g. thiohydantoin · CPC title

• C07D235/02

  condensed with carbocyclic rings or ring systems · CPC title